Core Viewpoint - Next week, a total of 38 stocks will be unlocked, with a combined market value of 39.63 billion yuan based on the latest closing prices [2]. Group 1: Stock Unlocking Details - Ningbo Yiyang will have 1.06 billion shares listed for circulation, primarily from the original shareholders' restricted shares, with an unlocking market value of 9.71 billion yuan [3]. - EVE Energy ranks second in unlocking market value, with 125 million shares to be unlocked, mainly from the placement of shares to targeted investors, totaling 8.62 billion yuan [3]. - In contrast, Longxun Co., Xinghao Pharmaceutical, and Yinlong Co. have relatively low unlocking pressure, with unlocking market values of less than 10 million yuan each [4]. Group 2: Unlocking Proportions - The stocks with the highest unlocking ratios include Ningbo Yiyang, Oke Technology, and Jingpin Special Equipment, all exceeding 50% [5]. Group 3: Institutional Attention - Eight stocks facing unlocking have garnered significant institutional attention, with over 30 institutions conducting research since the fourth quarter [7]. - Among these, Juhe Materials has a market value of 1.056 billion yuan facing unlocking, and has received research from 161 institutions. The company specializes in the research, production, and sales of fluorochemical products [8]. - Huadong Medicine has received research from 132 institutions and has begun exporting some of its pharmaceutical products internationally, while also expanding its medical aesthetics business globally [9]. Group 4: Stock Performance - Among the 38 stocks facing unlocking, the average stock price has decreased by 0.14% since December [8]. - Changying Tong has the highest price increase, with a cumulative rise of 9.94% in December, while Sanfu Xinke has the largest decline, with a cumulative drop of 12.37% [8].

Core Viewpoint - A total of 38 stocks will be unlocked for trading from December 8 to December 12, with a combined market value of 39.63 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - Ningbo Yiyang will have 1.06 billion shares available for trading, primarily consisting of original shareholders' restricted shares, with an unlocking market value of 9.71 billion yuan [1] - EVE Energy ranks second in unlocking market value, with 125 million shares to be released, mainly from targeted placement to institutional investors, amounting to 8.62 billion yuan [1] - Longxin Co., Xinghao Pharmaceutical, and Yinlong Co. have relatively low unlocking pressure, each with unlocking market values of less than 10,000 yuan [1] Group 2: Unlocking Proportions - Ningbo Yiyang, Oke Technology, and Jingpin Special Equipment have the highest unlocking ratios, all exceeding 50% [1]

Core Viewpoint - The article discusses the upcoming stock unlocks for 38 companies, with a total unlock market value of 21.678 billion yuan, highlighting the potential impact on stock prices and market sentiment [3]. Group 1: Upcoming Unlocks - Next week, 38 stocks will be unlocked, with a total market value of 21.678 billion yuan based on the latest closing prices [3]. - Among these, China Southern Airlines will have 804 million shares unlocked, with an unlock market value of 5.689 billion yuan [4]. - Filin Kesi will follow with 22 million shares unlocked, representing an unlock market value of 1.871 billion yuan [4]. Group 2: Market Performance - The average stock price of the 38 companies has decreased by 8.22% since November [7]. - Jiuqi Software has the highest price increase, with a rise of 13.74% in November, facing an unlock of 2.4883 million shares valued at 0.022 billion yuan [7]. - Huide Technology has the largest decline, with a drop of 33.96% in November, facing an unlock of 739,800 shares valued at 0.017 billion yuan [7]. Group 3: Institutional Research - Six companies, including Jianqiao Technology and Bojun Technology, have received institutional research in November [7]. - Jianqiao Technology will have 742 million yuan in market value unlocked, with 70 institutional research engagements [7]. - Bojun Technology has seen a significant improvement in operating cash flow, with an increase of over 70 million yuan compared to the previous quarter [7]. Group 4: Performance of Loss-Making Companies - Companies with performance losses, such as Hongyang Sun, Water Development Gas, and Zhongwang Software, face greater unlock pressure [8].

格隆汇11月21日｜下周将有38只股解禁，按照最新收盘价计算，合计解禁市值216.78亿元。南方航空解 禁市值最高，达56.89亿元，下周将有8.04亿股上市流通，主要为定向增发机构配售股份。菲菱科思的解 禁规模次之，下周将有0.22亿股上市流通，解禁股主要为首发原股东限售股份，解禁市值达18.71亿元。 解禁比例来看，必易微、吉冈精密、赛恩斯、菲菱科思等6股的解禁比例居前，均超30%。 ...

Core Viewpoint - CATL's stock has experienced a decline of over 4%, currently trading at 506 HKD, with a trading volume of 9.42 billion HKD. The upcoming unlocking of approximately 77.5 million shares held by cornerstone investors of its H-share IPO is a significant factor influencing market sentiment [1] Group 1: Stock Performance - CATL's H-share stock price has dropped by 3.8% to 506 HKD, with a total trading volume of 9.42 billion HKD [1] - Morgan Stanley has adjusted its target price for CATL's H-shares from 600 HKD to 575 HKD, indicating only a 6% upside potential from the current price [1] Group 2: Shareholder Actions - Major shareholder Huang Shilin is inquiring about transferring A-share holdings, with a preliminary transfer price set at 376.12 RMB per share, representing a discount of 21.8% compared to the H-share closing price of 526 HKD [1] - The inquiry for the transfer received 55 valid bids from various institutional investors, with a total effective subscription of 147 million shares, resulting in a subscription multiple of 3.2 times [1] Group 3: Market Outlook - Morgan Stanley maintains a positive outlook on CATL's A-shares, viewing it as a preferred choice in China's battery supply chain, with a target price of 480 RMB, suggesting a 19% upside potential from the latest closing price [1]

Core Viewpoint - CATL's stock has experienced a decline of over 4%, currently trading at 506 HKD, with a trading volume of 9.42 billion HKD. The upcoming unlocking of approximately 77.5 million shares held by cornerstone investors of its H-share IPO is a significant factor influencing market sentiment [1] Group 1: Stock Performance - CATL's H-share stock price has dropped by 3.8% to 506 HKD, with a trading volume of 9.42 billion HKD [1] - Morgan Stanley has adjusted its target price for CATL's H-shares from 600 HKD to 575 HKD, indicating only a 6% upside potential from the current price [1] Group 2: Shareholder Actions - Major shareholder Huang Shilin is inquiring about transferring A-share holdings at a price of 376.12 RMB per share, representing a discount of 21.8% compared to the H-share closing price of 526 HKD [1] - The inquiry for share transfer received 55 valid bids from various institutional investors, with a total subscription of 147 million shares, resulting in a subscription multiple of 3.2 times [1] Group 3: Market Outlook - Morgan Stanley maintains a positive outlook on CATL's A-shares, viewing it as a preferred choice in China's battery supply chain, with a target price of 480 RMB, suggesting a 19% upside potential from the latest closing price [1]

Core Viewpoint - Contemporary Amperex Technology Co., Limited (CATL) shares fell over 3%, closing at 523 HKD, with a trading volume of 277 million HKD, following the announcement of a major shareholder's intention to sell shares [1] Group 1: Shareholder Actions - Shareholder Huang Shilin plans to transfer 45.6324 million shares, representing 1% of the company's total share capital, due to personal funding needs [1] - As of November 13, Huang directly holds 466 million A-shares, accounting for 10.21% of the total share capital (including A-shares and H-shares), with 25.89 million shares being pre-IPO shares [1] Group 2: Market Analysis - JPMorgan recently recommended buying CATL's A-shares listed in Shenzhen while selling its H-shares in Hong Kong, as early key investors are approaching the end of their stock sale restrictions [1] - Starting November 19, cornerstone investors from CATL's May Hong Kong listing will be able to sell their holdings, potentially releasing nearly 50% of CATL's H-share float [1] - The report indicates that the unlocking of these shares could be a critical catalyst for reversing the premium of CATL's H-shares over A-shares [1]

Core Viewpoint - Morgan Stanley recommends buying CATL's shares listed in Shenzhen and selling those listed in Hong Kong due to the impending expiration of stock sale restrictions for early key investors [1] Group 1: Stock Market Analysis - Starting from November 19, cornerstone investors of CATL's Hong Kong listing will be able to sell their shares, potentially releasing nearly 50% of CATL's H-shares into circulation [1] - The report indicates that the unlocking of these shares could be a key catalyst for reversing the premium of CATL's H-shares over A-shares [1] Group 2: Performance Comparison - Since its Hong Kong listing six months ago, CATL's H-shares have surged by 116%, while its A-shares have only increased by 60% during the same period [1] - Currently, after adjusting for exchange rate factors, CATL's H-shares are approximately 25% more expensive than its A-shares, which is unusual as most companies listed in both markets typically see A-shares trading at a premium to H-shares [1]

Core Viewpoint - The company, Huaxia Eye Hospital, has announced the lifting of restrictions on shares issued prior to its initial public offering (IPO), allowing for increased liquidity in the market [1][2]. Group 1: Share Structure and Restrictions - After the IPO, the total share capital of the company is 56 million shares, with 503,663,671 shares subject to trading restrictions, accounting for 89.94% of the total [1]. - As of the announcement date, the total share capital has increased to 84 million shares, with 511,171,125 shares under trading restrictions, representing 60.85% of the total [2]. - The lifting of restrictions involves 238,830,000 shares, which is 28.43% of the total share capital [2]. Group 2: Shareholder Information - The restricted shares are held by two shareholders, with a total of 511,170,000 shares, which is 60.85% of the total share capital [3][4]. - The major shareholders include Huaxia Medical Investment (Xiamen) Co., Ltd. and Su Qingcan, who is the chairman and general manager of the company [4]. Group 3: Financial Performance and IPO Details - The company raised a total of 305.28 million RMB from the IPO, with a net amount of 276.85 million RMB after deducting issuance costs [5]. - The original fundraising target was 77.85 million RMB, indicating a significant oversubscription of 198.99 million RMB [5]. - The company was listed on the Shenzhen Stock Exchange's ChiNext board on November 7, 2022, with an issue price of 50.88 RMB per share [5].

Group 1 - The core viewpoint of the article highlights the significant revenue growth and profitability turnaround of Cambrian-U (688256) in Q3 2025, with a revenue of 1.727 billion yuan, a year-on-year increase of 1332.52%, and a net profit of 567 million yuan, marking a return to profitability [1] - For the first three quarters of 2025, Cambrian-U reported a revenue of 4.607 billion yuan, up 2386.38% year-on-year, and a net profit of 1.605 billion yuan, indicating a successful market expansion in AI applications [1] - Cambrian-U's stock price reached a peak of 1595.88 yuan per share in late August, making it the highest-priced stock in A-shares, although it closed at 1247.68 yuan per share recently, with a market capitalization of nearly 522 billion yuan [1] Group 2 - Next week, 54 stocks will face a lock-up expiration, with a total unlock market value of 71.709 billion yuan based on the latest closing prices [3] - Huibo Yuntong will have 157 million shares listed for circulation next week, with an unlock market value of 8.428 billion yuan, primarily from the original shareholders' lock-up [4] - Among the stocks facing lock-up expiration, the average price decline in October is 5.25%, with Hai Tong Development leading with a 24.12% increase [6]